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Introduction 
Osteoporosis is a disorder that leads to enhanced bone fragility through a decrease in the mass 
as well as deterioration of the microarchitecture of bones. Owing to its high prevalence and 
negative impact on quality of life, osteoporosis is the third most important public health 
disorder (after malignancies and cardiovascular disease), afflicting 200 million people 
worldwide [1]. Oral bisphosphonates are routinely prescribed for treatment for patients with 
osteoporosis. Adequate calcium and vitamin D sufficiency of the body is essential for 
antiresorptive treatment to be effective. According to HORVÁTH et al., serum 25-
hydroxyvitamin D3 level is lower than normal in 40% of elderly nursing home residents, 
whereas data from BHATTOA et al. reflect the same in 56.7% of postmenopausal women [2, 
3]. Some studies demonstrated statistically significant reduction of fractures during five years 
of high dose (100 000 E every four months) treatment with vitamin D3 [4], but others not  [5-
7]. According to a recent study, in 8 to 25 per cent of osteoporotic patients, bone loss 
continues despite adequate treatment with bisphosphonates, administered in combination 
calcium and vitamin D3 supplementation [8]. A proportion of these patients may have 
functional hypovitaminosis D potentially resulting from insufficient intake (despite 
supplementation), impaired activation, genuine resistance to vitamin D3  or secondary 
hyperparathyroidism [9]. In the remainder, the cause underlying the lack of bisphosphonate 
effects is unknown. 
In osteoporosis, genuine resistance to bisphosphonates is probably non-existent or may be 
considered extremely uncommon, at the least. In Paget’s disease, by contrast, where therapy is 
aimed at achieving complete biochemical remission, resistance to bisphosphonates has been 
demonstrated by several researchers. The lack of a complete biochemical remission is 
regarded by some as the criterion for bisphosphonate resistance [10], whereas according to 
others [11], the latter is established by a lower than 50-per-cent decrease in serum alkaline 
phosphatase (AP) level. Notwithstanding the criteria, the prevalence of resistance varies with 
different bisphosphonates in the range between 83% (etidronate [10]) and 11% (zolendronate 
[12]). 
According to additional, relevant evidence, the efficacy of activated analogues of vitamin D 
(alfacalcidol, calcitriol) in reducing bone fractures and increasing bone density is superior to 
that of native vitamin D. This has been demonstrated by several studies in various disease 
forms, i.e. in postmenopausal osteoporosis, as well as in osteoporosis related to inflammatory 
joint disease, or glucocorticoid therapy [13-16].  
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This study was intended to ascertain: 
1. whether replacing vitamin D3 with alfacalcidol is followed by an increase in BMD (i.e. 
bisphosphonate resistance can be overcome) in patients not responding to treatment with a 
bisphosphonate administered in combination with supplemental calcium and conventional 
vitamin D3; 
2. the incidence of hypovitaminosis D3 in the study population; 
3. the changes occurring in biochemical markers of bone turnover during one year of 
treatment with alfacalcidol, 
4. the frequency of adverse events associated with the use of alfacalcidol. 
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Patients and methods 
Patients 
Seventy-six patients were enrolled into the study conducted between January 2006 and March 
2007. The duration of follow-up was 12 months on average. Inclusion criteria were: 
diagnosed postmenopausal or senile osteoporosis (in females) or idiopathic osteoporosis in 
males, and greater than 3% decrease in BMD – as demonstrated by axial DEXA – despite 
adequate treatment (vitamin D3 400-1000 U/day, calcium 1000 mg/day and alendronate 
70 mg/week) for a year or longer. Exclusion criteria comprised established secondary 
osteoporosis, other forms of calcipenic osteopathy, hypercalcaemia, and history of renal 
calculosis. The male-to-female ratio was 4:72; mean age of the study population was 70.5 
(±8.2) years. Ten patients had a history of at least one prevalent vertebral or low-trauma 
peripheral fracture. The average serum 25-hydroxyvitamin D3 level was 72,2± 36,2 nmol/l at 
the starting and  74,1 ± 34,0 nmol/l at the end of the study (the difference was not significant 
statistically). Below normal serum 25-hydroxyvitamin D3 level (<75 nmol/l) was found in 38 
patients, along with elevated (>72 pg/ml) serum PTH level in 23 of these subjects. The mean 
glomerular filtration rate (GFR) was 85,3 ml/min/1,73m
2
 at baseline and 4 patients had GFR 
lower than 60 ml/min/1,73 m
2
 at starting of the study, 2 of them had elevated serum PTH 
level. In the included patients, the average administered dose of D3 vitamin was 530 U/day 
along with 1000 mg of calcium supplementation before the starting of the study. 
Study design 
During the follow-up period of one-year on average, control visits were scheduled at baseline 
and at 3-month intervals thereafter. At baseline, a detailed history (concomitant diseases, 
fractures, osteoporosis and risk factors) was recorded along with appraisal of clinical status by 
obtaining a lateral x-ray of the lumbosacral spine and performing a laboratory screen (ESR, 
CRP, CBC, serum calcium, phosphorus, BUN, creatinine, GOT, GPT, AP, albumin, 
osteocalcin, 25-hydroxyvitamin-D3, parathormon [PTH] levels, urinary calcium/creatinine 
[UCa/Cr] and deoxypyridinoline crosslinks/creatinine [D-Pyr/creatinine] ratios). Bone density 
was measured in both peripheral bones (DTX200) and in the axial skeleton (DEXA, Lunar 
DPX Pro) and BMD values obtained from the radius distal segment, as well as the means of 
the values measured in the 1
st
 through 4
th
 lumbar vertebrae were taken into account. Serum 
calcium level and urinary calcium/creatinine ratio were determined at control visits repeated 
at 3-month intervals. After one year, information was gathered on fractures and renal 
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calculosis that had occurred during the follow-up period, as well as osteodensitometry, 
lumbosacral x-ray, and laboratory screen were repeated. 
Treatment protocol 
The pre-existing regimen of alendronate 70 mg once per week was left unchanged, but 
conventional vitamin D3 and calcium treatment was replaced with 0.5 µg/day alfacalcidol (1α-
hydroxvitamin D3). The calcium supplementation was stopped also. 
Endpoints 
The primary endpoint of the study was defined as the change measurable (by DEXA) in bone 
mineral density (BMD) of the forearm and of axial bones one year after the introduction of 
alfacalcidol treatment. Secondary endpoints included changes in clinical chemistry parameters 
(serum calcium, phosphorus, and alkaline phosphatase levels), biochemical markers of bone 
turnover (serum osteocalcin, PTH, urinary D-Pyr/creatinine), UCa/Cr ratio determined in 
first-voided morning urine, treatment-emergent adverse reactions, and osteoporotic fractures 
that occur during follow-up. 
Statistical analysis  
The differences between the values of study parameters (BMD; serum Ca, P, AP, osteocalcin, 
PTH levels; urinary D-Pyr/creatinine and UCa/Cr ratios) determined at two time points were 
analysed using the SPSS 15.0 software package. First, the normality of differences was 
checked with the Kolmogorov-Smirnov test (normal distribution would allow performing a 
parametric [t or d] test). The differences between the paired values of all nine variables were 
significantly different from the normal distribution (p<0.01 for UCa/Cr and p<0.001 for the 
rest). As the data were unsuitable for analysis with the t-test, non-parametric Wilcoxon 
signed-rank test was performed to check the uniformity of repeated measurements. (This 
method is a non-parametric alternative to performing a paired t-test.) 
 
Results 
a) Changes in BMD during follow-up 
The median of changes as well as the minimal and maximal changes are summarised in 
Table 1.  
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  Unit Median Minimum Maximum 
Se Calcium mmol/l 0.06 -0.09 1.13 
Se Phosphate mmol/l -0.05 -0.49 0.3 
Alkaline phosphatase U/l -13 -46 287 
Parathormone pg/ml -10.7 -150 22.5 
Urinary Ca/creatinine   0.1 -0.32 0.49 
Osteocalcin ng/ml -0.4 -5.8 4.2 
BMD of forearm g/cm² 0.007 -0.011 0.039 
BMD of lumbar 1-4 
vertebrae 
g/cm² 0.012 -0.998 0.116 
Relative change of forearm 
BMD 
% 2.18 -3.5 16.3 
Relative change of lumbar 
BMD 
% 1.38 -11.3 15.8 
Deoxypyridinoline 
crosslinks/creatinine  
nmol/mmol -0.2 -15.69 0.12 
 
Table 1: Median, minimal and maximal changes in various parameters as a result of treatment 
 
After treatment for 396,5 ± 21,3 days with alendronate – with no change in the original 
dosage regimen of 70 mg/week, but – in combination with 0.5 µg/day alfacalcidol instead of 
the previously prescribed conventional vitamin D3 (administered with calcium), we observed 
the following changes (median values): forearm BMD increased by 0.007 g/cm², and lumbar 
(L1-4) BMD increased by 0.012 g/cm². The changes in T-scores showed rather high scatter. 
The relative changes in BMD values were 2.18% and 1.38% for the forearm and lumbar 
vertebrae, respectively. BMD changes that have occurred during one-year follow-up are 
shown in Figure 1. Box and whiskers plots are summarizing the median, quartiles, and 
extreme values. The box represents the interquartile range which contains the 50% of values. 
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The whiskers are lines that extend from the box to the highest and lowest values, excluding 
outliers. A line across the box indicates the median. 
Compared to baseline values, densitometry results (both BMD values and T-scores) obtained 
after one-year treatment revealed statistically significant improvement in both regions 
(Wilcoxon’s signed rank test, p<0.001).  
b) Changes in clinical chemistry parameters 
At baseline, mean serum calcium level was 2.34 (±0.106) mmol/l, phosphorus level was 1.18 
(±0.169) mmol/l, and UCa/Cr ratio measured in first-voided morning urine was 0.25 (±0.161). 
After one year of treatment, serum calcium level increased by 0.06 mmol/l (median), while 
serum phosphorus level decreased by 0.05 mmol/l. Urinary Ca to creatinine ratio measured in 
first-voided morning urine increased by 0.1 (median). All these changes were significant 
(Wilcoxon’s signed rank test, p<0.001) (see Figure 2). The decline of serum alkaline 
phosphatase level over the follow-up period by a median of 13 U/l was also significant, but 
clinically not relevant (see Figure 3).  
c) Changes in biochemical markers of bone turnover 
Changes in serum parathormone (PTH) level were as expected. At baseline, elevated PTH 
was ascertained in 32 patients; this number decreased to 16 during the one-year follow-up. 
The median change in serum PTH level was  significantly lower one year later (median 
change: -10.7 pg/ml) (Figure 3). Serum osteocalcin level decreased by 0.4 ng/ml (median) 
after treatment; this was accompanied by a decrease in the D-Pyr/creatinine ratio by 0.2 
nmol/mmol (p<0,001) (Figure 3). Although the changes showed high scatter, they proved to 
be highly significant (Wilcoxon’s signed rank test, p<0.001). The ranges of relative changes 
expressed as percentages of the base values for all parameters (Figure 4). 
d) Adverse events 
Mild hypercalcaemia (serum calcium level <3 mmol/l) was observed in 3 patients; no other 
clinically relevant adverse reactions were seen. There was no significant increase in urinary 
calcium based on alendronate therapy. 
e) New fractures 
As stated above, ten patients had a history of at least one prevalent vertebral or low-trauma 
peripheral fracture at starting of the study. Four new vertebral and two peripheral (wrist) 
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fractures were recorded during follow up. Two of the vertebral fractures were sustained by 
patients with a prevalent vertebral fracture. 
Discussion 
Some data from the literature suggest that activated vitamin D derivatives (alfacalcidol, 
calcitriol), also called D-hormone analogs, are superior to conventional vitamin D, as regards 
the mitigation of fracture risk. In their meta-analysis of 33 clinical studies, RICHY et al. found 
a 13.4-per-cent (delta RD, 95% CI 7.7-19.8) reduction of fracture risk during the use of 
activated vitamin D3 derivatives, compared to a mere 6% (delta RDi, 95% CI 1-12) 
accomplished by treatment with conventional vitamin D3 [ 13]. The rate difference (RD) was 
statistically significant (ANOVA-1; P< 0.001) RINGE et al. studied the changes of BMD and 
bone fractures in patients with glucocorticoid-induced osteoporosis, over 3 years of treatment 
with either alfacalcidol or vitamin D3 – both administered with calcium supplementation of 
500 mg daily. Changes in the BMD of the lumbar spine were 2.4% vs. -0.8% (p<0.0001), and 
of the femoral neck 1.2% vs. 0.8% (p<0.006), respectively. The proportion of patients who 
have sustained at least one new vertebral fracture was 9.7% in the alfacalcidol and 24.8% in 
the control group (risk reduction: 0.61, p=0.005), whereas the proportions of patients with at 
least one new non-vertebral fracture were 15% vs. 25% (risk reduction: 0.41, p=0.08). Taking 
the occurrence of any type of incident fractures into account, the above proportions were 
19.4% vs. 40.6%, respectively (risk reduction: 0.52, p<0.001) [14]. 
During the AAC study published in 2007, 30-30 patients were randomised into either of the 
following 3 treatment arms: a) alfacalcidol 1 µg + calcium 500 mg/day; b) alendronate 
70 mg/week + calcium 1000 mg/day + vitamin D3 1000  IU/day; c) alendronate 70 mg/week + 
calcium 500 mg/day + alfacalcidol 1 µg/day. During the 2 years of follow up, bone density of 
the lumbar spine and of the total hip increased by 3%/1.5%,  5.4%/2.4%, and 9.6%/3.8%, 
respectively. The magnitude of changes observed in patients treated with alendronate + 
alfacalcidol + calcium was significantly greater than of those seen in the other two groups 
(p<0.0001 for  lumbar BMD and p<0.0002 for femur BMD). The number of new osteoporotic 
(vertebral + non-vertebral) fractures occurring over 2 years of treatment in the three treatment 
groups was 9, 10, and 2, respectively – this finding is also in support of the favourable effect 
of alfacalcidol and  especially of the combination of alendronate + alfacalcidol on fracture 
prevention [16]. 
As suggested by several studies, administering antiresorptive agents (e.g. bisphosphonates) 
with activated vitamin D3 derivatives may increase the success of therapy. The beneficial 
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effects of alfacalcidol on intestinal calcium absorption, osteoid mineralization, muscle 
function and motor coordination, serum PTH level, and the risk of falls may substantially 
enhance the efficacy of treatment with bisphosphonates [17-18].  
The anabolic effect of alfacalcidol on bone is supported also by in vivo and in vitro data. 
Under the effect of alfacalcidol, osteoblasts have been shown to release various growth 
factors (TGF-β, IGF-1 and -2, bone morphogenetic proteins [BMPs], bone matrix proteins 
[collagen I, osteocalcin, osteopontin]) and thereby counterbalance the reduction of bone 
turnover during treatment with bisphosphonates [18-21]. This osteoanabolic effect of 
alfacalcidol administered in combination with alendronate has been demonstrated by several 
studies [21-24]. 
Our study was conducted on patients whose bone density was declining despite adequate 
treatment with a bisphosphonate and supplementation of calcium plus conventional vitamin 
D3 since a year at least. Patients with renal impairment or secondary osteoporosis were not 
allowed to participate in the study. Notwithstanding this, the study population included a 
substantial number of patients with decreased serum 25-hydroxyvitamin D3 levels (n=38), 
accompanied by higher than normal serum PTH level (n=23). This might suggest a potential 
relationship between resistance to bisphosphonates and the level of vitamin D3 insufficiency 
and the increase of serum PTH. Persistence of secondary hyperparathyroidism reduces BMD 
response to alendronate in older women with osteoporosis [9]. The improvement of the 
biochemical markers of bone turnover and increasing BMD indicate that patients apparently 
resistant to treatment with a bisphosphonate plus supplementation with calcium and 
conventional vitamin D3 are more likely to benefit from combination therapy with a 
bisphosphonate and alfacalcidol [9]. The enhanced efficacy of alendronate and alfacalcidol in 
combination is probably related to the synergism between the considerably different modes of 
action of the two components. In particular, the antiresorptive effect of alendronate is 
favourably supplemented by the mitigation of osteoclastogenesis [23, 25] and reduction of 
serum PTH level, along with the stimulation of osteoblast activity [21], improvement of bone 
quality [15,23] and the microarchitecture of trabecular bone by alfacalcidol [23]– which also 
enhances muscle strength and thereby activates the ‘mechanostat’ function of the skeleton 
[18]. The whole array of these effects might explain the outstanding effect on bones [17-18, 
24]. Further elucidation of these mechanisms would require large-scale studies with fracture 
endpoints, defined in addition to monitoring changes in bone density. 
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Although the lack of a control group may be considered a potential flaw of this study, the 
inclusion of untreated patients losing more than 3 per-cent of their bone density each year 
would have been ethically questionable at the least.  
 
Conclusion 
As shown by the results of this study, patients whose bone density decreases inexorably 
despite adequate treatment with alendronate and supplemental calcium and vitamin D3 might 
benefit from a  combined treatment of alendronate with alfacalcidol. The latter combination 
accomplished significant increase of BMD along with improvement of the biochemical 
markers of bone turnover, but without any substantial increase in the incidence of adverse 
effects. 
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Figure legends 
 
Figure 1. The changes of BMD during follow-up. Box and whiskers plots are summarizing 
the median, quartiles, and extreme values. 
Figure 2. Changes of serum calcium and phosphorus levels, as well as of UCa/creatinine ratio 
during the study. 
Figure 3. The change of serum alkaline phosphatase activity (U/l), parathormone level 
(pg/ml), osteocalcin level (ng/ml ) and of urinary deoxypirydinoline 
crosslinks/creatinine (D-Pyr/creatinine, nmol/mmol) by the end of the follow-up.  
Figure 4. The ranges of relative changes expressed as percentages of the base values for all        
parameters. 
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1Figure 1. The changes of BMD during follow-up (g/cm²).
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1Figure 2. Changes of serum calcium and phosphorus levels (mmol/l), as well as of UCa/creatinine 
ratio during the study.
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osteocalcin level (ng/ml ) and of urinary deoxypirydinoline crosslinks/creatinine (D-Pyr/creatinine, 
nmol/mmol) by the end of the follow-up.
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